Hammerstrom Troy G, Beabout Kathryn, Clements Thomas P, Saxer Gerda, Shamoo Yousif
Department of Biosciences, Rice University, Houston, Texas, United States of America.
PLoS One. 2015 Oct 21;10(10):e0140489. doi: 10.1371/journal.pone.0140489. eCollection 2015.
The evolution of hypermutators in response to antibiotic treatment in both clinical and laboratory settings provides a unique context for the study of adaptive evolution. With increased mutation rates, the number of hitchhiker mutations within an evolving hypermutator population is remarkably high and presents substantial challenges in determining which mutations are adaptive. Intriguingly however, hypermutators also provide an opportunity to explore deeply the accessible evolutionary trajectories that lead to increased organism fitness, in this case the evolution of antibiotic resistance to the clinically relevant antibiotic tigecycline by the hospital pathogen Acinetobacter baumannii. Using a continuous culture system, AB210M, a clinically derived strain of A. baumannii, was evolved to tigecycline resistance. Analysis of the adapted populations showed that nearly all the successful lineages became hypermutators via movement of a mobile element to inactivate mutS. In addition, metagenomic analysis of population samples revealed another 896 mutations that occurred at a frequency greater than 5% in the population, while 38 phenotypically distinct individual colonies harbored a total of 1712 mutations. These mutations were scattered throughout the genome and affected ~40% of the coding sequences. The most highly mutated gene was adeS, a known tigecycline-resistance gene; however, adeS was not solely responsible for the high level of TGC resistance. Sixteen other genes stood out as potentially relevant to increased resistance. The five most prominent candidate genes (adeS, rpsJ, rrf, msbA, and gna) consistently re-emerged in subsequent replicate population studies suggesting they are likely to play a role in adaptation to tigecycline. Interestingly, the repeated evolution of a hypermutator phenotype in response to antibiotic stress illustrates not only a highly adaptive strategy to resistance, but also a remarkably efficient survey of successful evolutionary trajectories.
在临床和实验室环境中,超突变体对抗生素治疗的进化为适应性进化的研究提供了独特的背景。随着突变率的增加,进化中的超突变体群体中搭便车突变的数量非常高,这在确定哪些突变是适应性的方面带来了巨大挑战。然而,有趣的是,超突变体也提供了一个机会,可以深入探索导致生物体适应性增加的可及进化轨迹,在这种情况下,医院病原体鲍曼不动杆菌对临床相关抗生素替加环素的耐药性进化。使用连续培养系统,将临床分离的鲍曼不动杆菌菌株AB210M进化为对替加环素耐药。对适应群体的分析表明,几乎所有成功的谱系都通过移动元件的移动使mutS失活而成为超突变体。此外,对群体样本的宏基因组分析揭示了另外896个在群体中出现频率大于5%的突变,而38个表型不同的单个菌落共含有1712个突变。这些突变分散在整个基因组中,影响了约40%的编码序列。突变程度最高的基因是adeS,这是一个已知的替加环素耐药基因;然而,adeS并非替加环素高耐药性的唯一原因。另外16个基因被认为可能与耐药性增加有关。五个最突出的候选基因(adeS、rpsJ、rrf、msbA和gna)在随后的重复群体研究中持续出现,表明它们可能在适应替加环素方面发挥作用。有趣的是,超突变体表型对抗生素应激的反复进化不仅说明了一种高度适应性的耐药策略,也说明了对成功进化轨迹的高效探索。